department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Adbry · pharmadog

pharmadog
drugs
Adbry

drug

patient view →

tralokinumab

Marketedupdated 2mo ago

by LEO Pharma Inc

Approved

community read0 votes

all catalysts(7)

approval · 7

ADBRY (TRALOKINUMAB) — FDA approval

ADBRY (TRALOKINUMAB) — FDA approval

ADBRY (TRALOKINUMAB) — FDA approval

ADBRY (TRALOKINUMAB) — FDA approval

ADBRY (TRALOKINUMAB) — FDA approval

ADBRY (TRALOKINUMAB) — FDA approval

ADBRY (TRALOKINUMAB) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Adbry

generic

tralokinumab-ldrm

indication

Atopic Dermatitis (Atopic Eczema)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 5

drugADBRY32 co-mentions · 8 sources
tagApproval28 co-mentions · 7 sources
companyLEO Pharma Inc20 co-mentions · 8 sources
companyLeo Pharma AS14 co-mentions · 7 sources
tagRecall2 co-mentions · 1 sources

Trials studying tralokinumab

phase2Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)completedn=28
phase1A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjectscompletedn=101
phase3A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitisrecruitingn=195
—Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impactrecruitingn=30
phase3A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapycompletedn=235
phase3Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)completedn=794
phase3Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)completedn=136
phase3Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3completedn=380

more trials →